{'fraction_non_alphanumeric': 0.05719557195571956, 'fraction_numerical': 0.03228782287822878, 'mean_word_length': 4.896739130434782, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Clinical significances of combined detections of autoantibodies in patients with systemic lupus erythematosus].

OBJECTIVE
To evaluate the clinical significances of combined detections of the autoantibodies ANA, ANAs and anti-dsDNA in patients with systemic lupus erythematosus (SLE).


METHODS
ANA was tested by indirect immunofluorescent method (IIF), ENA was tested by Western blot and anti-dsDNA was measured with radioimmunoassay in the serum samples from patients with SLE (n=90), and from the comparison group (n=74) and healthy control group (n=53).


RESULTS
The sensitivity of anti-dsDNA, AnuA,anti-Sm in patients with SLE was 41.1%, 32.2% and 22.2%. The specificity of anti-dsDNA, AnuA, anti-Sm in SLE patients was all 97.3%. The positive likelihood ratios were 15.22, 11.93 and 8.22, respectively. The sensitivity and specificity reached 62.2% and 90.5%, respectively by combined determinations of anti-dsDNA, AnuA and anti-Sm.


CONCLUSION
The combined examinations of anti-dsDNA, AnuA, anti-Sms can improve the sensitivity and efficiency of laboratory diagnosis of SLE.